Cargando…
Aspects of prophylactic treatment of hemophilia
Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056524/ https://www.ncbi.nlm.nih.gov/pubmed/27766056 http://dx.doi.org/10.1186/s12959-016-0103-3 |
_version_ | 1782458918331482112 |
---|---|
author | Ljung, Rolf |
author_facet | Ljung, Rolf |
author_sort | Ljung, Rolf |
collection | PubMed |
description | Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors. |
format | Online Article Text |
id | pubmed-5056524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50565242016-10-20 Aspects of prophylactic treatment of hemophilia Ljung, Rolf Thromb J Review Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors. BioMed Central 2016-10-04 /pmc/articles/PMC5056524/ /pubmed/27766056 http://dx.doi.org/10.1186/s12959-016-0103-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Ljung, Rolf Aspects of prophylactic treatment of hemophilia |
title | Aspects of prophylactic treatment of hemophilia |
title_full | Aspects of prophylactic treatment of hemophilia |
title_fullStr | Aspects of prophylactic treatment of hemophilia |
title_full_unstemmed | Aspects of prophylactic treatment of hemophilia |
title_short | Aspects of prophylactic treatment of hemophilia |
title_sort | aspects of prophylactic treatment of hemophilia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056524/ https://www.ncbi.nlm.nih.gov/pubmed/27766056 http://dx.doi.org/10.1186/s12959-016-0103-3 |
work_keys_str_mv | AT ljungrolf aspectsofprophylactictreatmentofhemophilia |